Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

Q: What does this research mean for the field?

Mirikizumab provides sustained symptomatic, clinical, endoscopic, and histologic benefits over 4 years in patients with moderately-to-severely active ulcerative colitis. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Bruce E Sands; D Clemow; Geert D’Haens; Peter M Irving; Hiroyuki Kuge; Laurent Peyrin-Biroulet; Karen Samaan; Anil Gaur; Ravneet Arora; Kris Todd; R Moses; Axel Dignass

doi:10.1093/ibd/izag007

January 15, 2026Inflammatory Bowel Diseases

Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the long-term efficacy and safety of mirikizumab in patients with moderately-to-severely active ulcerative colitis.
Conducted an open-label extension study over four years
Included patients with prior biologic failure
Assessed symptomatic, clinical, endoscopic, and histologic outcomes
Mirikizumab provided sustained symptomatic benefits over four years
Patients experienced significant improvements in clinical and endoscopic measures
Histologic benefits were also observed in responding patients

Implication

Open-label extension study shows sustained benefits of mirikizumab in ulcerative colitis, supporting long-term use.

Abstract

Mirikizumab provided sustained symptomatic, clinical, endoscopic, and histologic benefits over 4 years in responding patients with moderately-to-severely active UC, including those with prior biologic failure. These treatment goals, which are integral to comprehensive disease management, support the long-term use of mirikizumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sands et al. (2026) studied this question.

synapsesocial.com/papers/69aa6eb1531e4c4a9ff58df6 https://doi.org/10.1093/ibd/izag007

View Full Paper

Ask AI

Bookmark

Share

Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

Key Points

Implication

Abstract

Discussion

Cite This Study

Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading